Редкое превышение целевых
показателей Hb
Терапия Мирцерой обеспечивает плавное и стойкое повышение уровня Hb, с минимальным риском превышения Hb более 13 г/дл. Как показано на графике, превышение целевого уровня Hb более 13 г/дл наблюдалось на 65% реже, чем при применении дарбэпоэтина альфа.
Литература:
- Macdougall IC, Walker R, Provenzano R, et al. C.E.R.A. corrects anaemia in patients with chronic kidney disease not on dialysis: Results of a randomized clinical trial. Clin J Am Soc Nephrol. 2007 In press.
- Klinger M, Aria M, Vargemezis V, et al. Intravenous C.E.R.A. administered twice monthly corrects haemoglobin levels in patients with chronic kidney disease on dialysis: results of AMICUS, a randomized prospective study vs epoetin given once to three times weekly. Am J Kidney Dis. 2007 In press.
- MIRCERA® Summary of Product Characteristics. F. Hoffmann-La Roche Ltd. 2007.
- Levin NW, Imbasciati E, Combe C, et al. Adequate Hb levels are maintained with IV C.E.R.A. (continuous erythropoietin receptor activator) administered up to once monthly in dialysis patients irrespective of age, gender or diabetic status. J Am Soc Nephrol. 2006;17:619A (abstract SA-PO206).
- Ryckelynck J-P, Harris K, Selga R, et al. SC C.E.R.A. (continuous erythropoietin receptor activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status. J Am Soc Nephrol. 2006;17:620A (abstract SA-PO210).
- Imbasciati E, Bernado M, Caraman P-L, et al. Stable haemaoglobin (Hb) levels are maintained with once-monthly C.E.R.A. in dialysis with varying C-reactive protein (CRP), albumin or dialysis adequacy. Nephrol Dial Transplant. 2007 In Press (abstract Suo005).
- Mann J, Locatelli F, Sulowicz W, et al. C.E.R.A. provides stable haemoglobin (Hb) levels in CKD patients on dialysis with and without coronary artery disease (CAD) or diabetes mellitus (DM) when administered once monthly. Nephrol Dial Transplant. 2007 In Press (abstract Suo002).
- Sulowicz W, Locatelli F, Ryckelynck J-P, et al. Once-monthly subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) maintains stable control in patients with chronic kidney disease on